EUVIMED · CrossrefJournal
Multiple Sclerosis Journal
ISSN 1352-4585 · SAGE Publications
Latest articles
Primary results of the supervised versus telerehabilitation exercise program for multiple sclerosis trial: A comparative effectiveness trial
Which patient-reported outcome measure of fatigue to use for multiple sclerosis studies? Part 1: A comparison of six measures raises fundamental questions
Disease-modifying treatment does not influence severity and recovery of the first relapse after treatment onset in RRMS: insights from four large-scale clinical trials
2026 ACTRIMS forum Kenneth P Johnson lecture. Autologous hematopoietic stem cell transplantation in multiple sclerosis and other neuroinflammatory conditions: Current evidence and remaining questions
When fatigue measures agree, but patients do not
Which patient-reported outcome measure of fatigue to use for multiple sclerosis studies? Part 2: simulation studies highlight broad implications for clinical outcomes analysis
Mapping myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and neuromyelitis optica spectrum disorders (NMOSD): A global review of publicly listed patient disease registries and databases
Myelin oligodendrocyte glycoprotein antibody–associated disease in a modern, population-based cohort
Rectal pallesthesia as a novel symptom of multiple sclerosis: A case report
Pelvic neurology meets multiple sclerosis
Multiple sclerosis relapse redefined: Effect of an MRI-supported relapse criterion on ublituximab outcomes in the ULTIMATE I and II trials
Lower recorded prevalence of Alzheimer’s disease in natalizumab-exposed older adults with multiple sclerosis: A hypothesis-generating observation
Emergence of natalizumab anti-drug antibodies during extended interval dosing in a patient with multiple sclerosis: A case report
Corrigendum
Corrigendum
Erratum to “Assessing diagnosis disclosure and concealment in multiple sclerosis: building a framework for moving forward”
Accelerometry-derived activity fragmentation as a predictor of brain atrophy and disability progression in multiple sclerosis
Reversible area postrema syndrome in a patient with GJB1 mutation mimicking neuromyelitis optica spectrum disorder
Prescription drug dispensations 15 years before multiple sclerosis onset: A matched cohort study, British Columbia, Canada
Comparative effectiveness of rituximab versus ocrelizumab in relapsing multiple sclerosis on clinical relapses and radiological outcomes in British Columbia, Canada
Genetic mimics of neuromyelitis optica spectrum disorder
Testing the construct validity of real-world digital mobility outcomes in multiple sclerosis
All anti-CD20 therapies are equivalent in treating MS: Yes
All anti-CD20 therapies are equivalent in treating MS: No
All anti-CD20 therapies are equivalent in treating MS: Commentary
Long-term efficacy of cladribine tablets: Results from the MAGNIFY-MS Extension study
Post-traumatic stress disorder in people with multiple sclerosis: A narrative review
Emergency department use before multiple sclerosis: Presenting complaints and discharge diagnoses
Diurnal step count patterns in progressive multiple sclerosis
Real-life walking speed: A new marker of progression in a primary progressive multiple sclerosis cohort study?
Volumes
2026 · 2602025 · 2452024 · 2652023 · 2452022 · 2902021 · 3192020 · 2962019 · 2842018 · 3092017 · 3132016 · 2952015 · 2662014 · 3202013 · 3152012 · 2972011 · 2192010 · 2072009 · 2372008 · 2142007 · 1942006 · 1312005 · 1322004 · 1602003 · 1082002 · 1262001 · 1462000 · 1621999 · 1711998 · 2161997 · 991996 · 991995 · 52
EUVIMED